Clinical Trial

A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer

Unknown Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 27, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center, single-arm, open-label, dose-escalation clinical study to evaluate the safety and anti-tumor efficacy of second-line systemic chemotherapy sequential NKG2D CAR-NK cell therapy for pancreatic cancer
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06503497
Lead Sponsor Zhejiang University
Conditions Pancreatic Cancer Non-resectable
Enrollment 30 participants
Start Date 2024-07-09
Primary Completion 2025-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-27